Measurement of serum PODXL concentration for detection of pancreatic cancer.
Measurement of serum PODXL concentration for detection of pancreatic cancer.
复制标题
DOI：
10.2147/ott.s155367
复制
发表时间：
2018
影响因子：
4
通讯作者：
Saibara T
中科院分区：
文献类型：
--
作者：
Taniuchi K;Tsuboi M;Sakaguchi M;Saibara T
本研究的目的是研究使用全血中的足糖萼蛋白（PODXL）和分泌珠蛋白家族1D，成员2（SCGB 1D 2）表达作为诊断生物标志物，以区分胰腺癌患者和对照参与者，与血清癌抗原19-9（CA 19 -9）相比，这是目前的临床标准。流式细胞仪检测胰腺癌细胞表面PODXL和SCGB 1D 2的表达。进行免疫印迹以确定在培养的胰腺癌细胞的培养基中是否可检测到PODXL和SCGB 1D 2。在2014年4月至2016年1月期间在高知医学院医院消化内科和肝病科接受治疗的23名胰腺癌患者和51名无胰腺疾病的对照个体的队列中进行了一项发现阶段临床研究。采用酶联免疫吸附法（ELISA）测定血清PODXL和SCGB 1D 2水平。PODXL和SCGB 1D 2积聚在培养的胰腺癌细胞的突起中，并且它们在细胞表面和来自这些细胞的培养液中均可检测到。发现阶段临床研究显示，PODXL的受试者工作特征曲线下面积（AUC）为0.96（95%置信区间[CI] 0.91-1.000），SCGB 1D 2为0.80（95% CI 0.67-0.94），CA 19 -9为0.78（95% CI 0.66-0.90）。因此，PODXL的AUC显著高于CA 19 -9的AUC（P = 0.006）。与单独SCGB 1D 2或CA 19 - 9的AUC相比，SCGB 1D 2与CA 19 - 9的组合没有显著增加AUC（0.83; 95%CI 0.70-0.96）（P = 0.563）。PODXL可能是一种新的、非侵入性的胰腺癌诊断生物标志物。
The aim of this study was to investigate the use of podocalyxin (PODXL) and secretoglobin family 1D, member 2 (SCGB1D2) expressions in whole blood as diagnostic biomarkers to distinguish between patients with pancreatic cancer and control participants, in comparison with serum cancer antigen 19-9 (CA19-9), which is the current clinical standard. Flow cytometric analysis was performed to determine the expressions of PODXL and SCGB1D2 on the surface of cultured pancreatic cancer cells. Immunoblotting was performed to determine whether PODXL and SCGB1D2 were detectable in the media of cultured pancreatic cancer cells. A discovery-stage clinical study was performed in a cohort of 23 patients with pancreatic cancer and 51 control individuals without pancreatic disease who had been treated in the Department of Gastroenterology and Hepatology at Kochi Medical School Hospital from April 2014 to January 2016. Serum PODXL and SCGB1D2 levels were measured by enzyme-linked immunosorbent assay (ELISA). PODXL and SCGB1D2 accumulated in the protrusions of cultured pancreatic cancer cells, and they were detectable both on the cell surface and in the cultured media from these cells. The discovery-stage clinical study showed that the area under the receiver-operating characteristic curve (AUC) was 0.96 (95% confidence interval [CI] 0.91–1.000) for PODXL, 0.80 (95% CI 0.67–0.94) for SCGB1D2, and 0.78 (95% CI 0.66–0.90) for CA19-9. The AUC for PODXL was thus significantly higher than that for CA19-9 (P = 0.006). The combination of SCGB1D2 with CA19-9 did not significantly increase the AUC (0.83; 95% CI 0.70–0.96) compared with the AUC for either SCGB1D2 or CA19-9 alone (P = 0.563). PODXL may be a novel, non-invasive diagnostic biomarker for the detection of pancreatic cancer.